HCPCS Level II code Q5160 designates a 10 mg unit of bevacizumab-nwgd (Jobevne), a biosimilar to bevacizumab used in oncology and select ophthalmology indications when appropriate. The code identifies the biologic product and strength for billing of the injected medication and is relevant across outpatient infusion settings nationally because biologic therapies drive significant drug spend and have evolving coverage policies.

Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context for bevacizumab biosimilars, the typical sites of service where Q5160 is billed, and what national payers commonly consider when covering biosimilar oncology agents. The briefing outlines the types of benchmarks and policy elements typically reviewed for this code, including billing units, infusion administration context, and product-specific coverage considerations.

This summary supports stakeholders—hospital administrators, billing professionals, and policy analysts—in understanding where Q5160 fits into the drug billing landscape, what payer coverage alignment to expect, and which operational and policy levers are most relevant when managing biosimilar bevacizumab use in outpatient infusion environments.